2026
Life Sciences Technology Landscape
Overview
Alberta’s life sciences ecosystem has grown into a sizeable base of companies, and 2026 shows both its potential and where it has room to grow.
Start Alberta currently tracks 390 life sciences companies in the province. Among those with valuation data, reported valuations have grown more than sevenfold on average since 2018, though a small group of companies with large gains drives much of that average. Fourteen companies have reached Series A or beyond, and disclosed funding and acquisition value across the ecosystem tops $1.5 billion.
So far in 2026, disclosed funding and acquisition value has reached $374 million across 20 transactions involving 17 companies. Most of that comes from one deal: U.S.-based Grindr’s agreement to acquire Calgary-based PurposeMed, announced in October, at a base price of about $347 million (US$250 million). The deal is expected to close by year-end.
Set that deal aside and the rest of the year adds up to about $27 million. Four companies closed seed or Early VC rounds, and others drew on grants and private placements, including $6 million in federal funding for Northern RNA. No Alberta life sciences company has disclosed a Series A or later round so far this year.
The picture that emerges is a large base of early-stage companies and at least one significant exit, but relatively few companies reaching growth-stage rounds. If that pattern holds, helping more companies through Series A may be one of the sector’s biggest opportunities.
* See Methodology for transactions definitions.
Life Sciences 2026 Key Figures
Capital Landscape
From 2018 to 2026, Alberta life sciences companies raised about $372 million in disclosed venture funding. Annual totals swing widely, and a handful of large rounds explain most of that movement.
The two biggest years were 2020, at about $95 million, and 2024, at about $96 million. In each, one or two large rounds made up most of the total: OncoQuest’s $67-million round in 2020, and rounds of $37 million for Fluid Biomed and $27 million for Orpyx Medical Technologies in 2024. Across the full period, rounds of $15 million or more account for almost half of all disclosed venture funding, and only five companies raised them. In practice, the sector’s annual total depends heavily on whether one of these larger rounds closes in a given year.
Early-stage funding has been steadier. Pre-seed and seed rounds added between $6 million and $18 million a year from 2018 to 2025, and Series A-sized rounds appeared in most years. Larger rounds were less consistent: rounds of $15 million or more closed in only four of those eight years, with none in 2019, 2022, 2023 or 2025. So far in 2026, the only disclosed venture round is FLORA’s $7-million seed round.
Exits have been rare but sizeable. Thoma Bravo acquired Circle Cardiovascular Imaging for about $277 million (US$213 million) in 2022, and Grindr’s pending acquisition of PurposeMed is valued at about $347 million.
The data points to a gap between early-stage funding and larger follow-on rounds. On its own, the data can’t tell us whether that reflects limited capital, fewer companies ready for that stage, or both, but either way, it’s a gap worth working on.
The combined enterprise value of Alberta life sciences companies rose from about $1.4 billion in 2018 to about $4.5 billion in 2026. Part of that increase reflects growth in existing companies, and part reflects more companies having valuations, as more startups have entered the sector and data tracking has become more thorough. That value is concentrated: five companies account for about four-fifths of the 2026 total. Biotechnology holds the largest share, and most of it comes from one public company. Aurinia Pharmaceuticals accounts for about $2.5 billion of the $2.7-billion biotech total. Health platforms rose from $122 million to $802 million as the number of valued companies grew from seven to 27. Two acquisitions make up most of that total: Circle Cardiovascular Imaging and the pending PurposeMed deal. Medical devices grew from $60 million to $460 million, and that growth is spread across a broader group of companies as more startups enter the space.
Overall value still rests on a small number of large companies and exits, but medical devices show signs of a wider base taking shape.
The five largest transactions in 2026 add up to about $369 million, almost all of the year’s disclosed funding and acquisition value. One deal dominates: Grindr’s pending acquisition of PurposeMed, at about $347 million, is roughly 50 times the size of the next-largest transaction.
The other four range from $3 million to $7 million each and total about $23 million. They came through different routes: FLORA raised a seed round, XORTX Therapeutics and Resverlogix raised money as public companies, and Northern RNA received federal funding. FLORA’s is the only venture round in the top five, and the only one with foreign investors alongside Canadian ones.
Outside the PurposeMed deal, disclosed funding in 2026 came in small amounts from a mix of public, private and government sources, with little venture capital at scale.
Of the 390 life sciences companies Start Alberta currently tracks, 41 (about 10 per cent) are classified as bootstrapped, meaning they have no recorded external investment. That share likely reflects the sector’s capital needs: life sciences companies, particularly in biotechnology and pharmaceuticals, typically need outside funding to get through long development and regulatory timelines before they generate revenue.
The bootstrapped group is small, but it suggests some Alberta life sciences companies are finding ways to grow without outside investors.
Flora | Fertility insurance that belongs to the woman, not her employer
Flora Fertility is taking on one of the biggest out-of-pocket costs in health care: building a family when it doesn’t come easily. The company is dual-headquartered in Calgary and Chicago and offers personally owned coverage for fertility diagnostics, medications, IUI and IVF, up to $50,000, for women aged 20 to 34 in the U.S., at an average of $40 a month. Because the policy isn’t tied to a job, women keep their coverage through changes in employment or personal circumstances. For co-founders Dr. Christy Lane and Laura McDonald, the mission is personal: Calgary’s Lane went through three years of fertility treatment, all paid out of pocket, before having the first of her three children, while McDonald watched a close family member face the same financial barriers. Their track records fit the problem, too. Lane co-founded the Stanford Wearable Health Lab and built Vivametrica, whose underwriting models are still used by global life insurers and reinsurers, and McDonald built and sold Canada’s largest financial media company focused on women and wealth.
Investors are paying attention. After a $1.5-million round in October 2024, Flora closed a US$5-million seed round in April 2026 led by Iowa’s ManchesterStory, with BDC participating, and plans to use the funds to grow its customer base and bring its coverage into settings like OB/GYN offices. In September, Flora partnered with cycle-tracking app Clue, giving policyholders complimentary access to Clue’s premium subscription. “Flora is building something that has never existed before — affordable, portable fertility insurance that meets the next generation of women exactly where they are,” said principal at ManchesterStory, Nicole Gunderson. “The InsurTech opportunity here is enormous, and the Flora team has the expertise, technology, and vision to define this category.”
PulseMedica | Laser-focused on a problem eye care has long overlooked
PulseMedica is going after something most people have noticed at some point: the specks and cobwebs that drift across their vision. About half of adults have eye floaters, and for 5 to 10 per cent of them the impairment is severe, with no safe, non-invasive treatment available. The Edmonton company, a University of Alberta spinout co-founded in 2018 by Nir Katchinskiy and Eric Martin, is building a 3D image-guided femtosecond laser platform to screen and treat floaters, and eventually other vitreoretinal diseases. CEO Katchinskiy studied femtosecond laser pulses for his PhD, working at a timescale of one millionth of a billionth of a second. Early on, he noted that floaters had few treatment options and his technology was well suited to them; once the team could detect and track floaters, treating them was the logical next step.
The momentum is real. PulseMedica stepped into the spotlight in July 2024, announcing $12 million in pre-Series A funding led by Saltagen Ventures and bringing its total raised since 2020 to more than $16 million, including $6.5 million from a multinational strategic investor in 2023. By then, it had built seven prototype devices and filed 14 patents. Retina specialist Dr. John Pollack joined its board in 2025, and this year the company won the health.tech startup competition in Basel and was named Most Edmonton Startup of the Year by the YEG Startup Community Awards. With clinic-ready prototypes in development and its first-in-human study on the horizon, PulseMedica is edging closer to giving millions of people a clearer view, and proving that world-class medical technologies can be built right here in Alberta.
Talent Pipeline
The number of people working in Alberta’s life sciences technology companies appears to be growing, though improved data coverage makes it hard to say how much of that is new hiring. Tracked headcount rose from about 1,550 in 2021 to about 2,980 in 2026. While the number of companies has grown in that time, some of the headcount increase likely reflects more companies being captured in the data rather than existing teams growing quickly.
Yearly figures move around for the same reason, so the overall trend tells a clearer story than any single year. Most of the increase came between 2021 and 2022, and headcount has held at roughly 2,400 to 3,000 since then.
What stands out more is how small most of these companies are. The median company has five employees, and about two-thirds have fewer than 10. Only 11 have reached 50 or more, led by Aurinia Pharmaceuticals, Circle Cardiovascular Imaging and PurposeMed. It’s a sector built largely on small teams, with only a handful of companies operating at scale.
Life Sciences Innovation Across Canada
Canada’s life sciences sector is concentrated in four provinces, which together are home to more than nine in 10 of the country’s 4,863 tracked companies. Ontario leads with 47 per cent, followed by British Columbia (20 per cent), Quebec (18 per cent) and Alberta (8 per cent).
Disclosed funding and acquisition value across Canada reached about $9.3 billion so far in 2026, led by Ontario ($4.8 billion), British Columbia ($2.4 billion) and Quebec ($1.7 billion). In each of those provinces, a few large public-market deals and acquisitions make up much of the total.
Alberta ranks fourth, with $374 million across 20 transactions. Most of that comes from Grindr’s pending acquisition of Calgary-based PurposeMed, one of the largest life sciences transactions in Canada this year. Alberta is home to 8 per cent of the country’s life sciences companies but accounts for about 4 per cent of 2026 transaction value, a gap consistent with the shortage of larger funding rounds noted earlier in this report.
Canadian investors take part in most of the country’s life sciences deals. Of the 159 transactions in 2026 with named investors, 95 involved only Canadian investors, and another 26 brought Canadian and international investors together. That means Canadian capital was part of about three in four deals this year.
International investors and buyers acted alone in 38 transactions. By value, the split between Canadian-only deals ($2.2 billion) and international-only deals ($2.4 billion) is close, but a handful of large transactions drive both totals. Most of the Canadian-only amount comes from a single debt financing for Apotex, led by Canadian banks, while GSK’s acquisition of 35Pharma and Grindr’s pending acquisition of Calgary-based PurposeMed account for much of the international total.
So while Canadian investors take part in most of the sector’s deals, the largest transactions this year were a mix of domestic bank debt and foreign acquisitions. Alberta saw international activity on both the acquisition and investment side, with PurposeMed’s sale to a U.S. buyer and FLORA’s seed round, which included foreign investors alongside Canadian ones.
Top 10 Canadian Life Sciences Transactions (2026)
Methodology
Data source and extraction
All data in this report comes from Dealroom, accessed through the Start Alberta platform and exported in October 2026. Figures for 2026 cover January 1 to October 20, 2026. The analysis draws on two datasets:
|
Population |
Dealroom filters |
Used for |
|---|---|---|
|
Alberta reporting population |
Founding or HQ location in Alberta, Start Alberta tag, Health industry, closed companies excluded |
Alberta company counts, funding, valuation, enterprise value, employment and the taxonomy |
|
Canadian comparison population |
Founding or HQ location in Canada, Health industry, closed companies excluded, then cleaned as described under Canadian comparison population |
Provincial comparisons, 2026 transactions and investor origin |
Canadian comparison population
The Canadian comparison starts with the 7,006 active companies Dealroom tags as Health. Two groups are then removed: companies with no headquarters city listed, and companies tagged as Health that aren’t health or life sciences businesses.
Resource companies are identified by keywords in the company name: gold, silver, metal, mining, oil, energy, carbon, mineral, exploration, resource, petroleum, power and cobalt. Other non-health businesses and service providers (including in-person clinics and care providers) are identified by name and manually reviewed.
|
Reason for removal |
Companies removed |
|---|---|
|
No HQ location |
1,318 |
|
Mining, metals, oil and gas, energy |
70 |
|
Other non-health businesses |
120 |
|
Clinics, pharmacies, hospitals and care providers |
285 |
|
Dental clinics and labs |
62 |
|
Optometry and eye care |
28 |
|
Marketing, consulting and other business services |
53 |
|
Total |
1,936 |
Transactions and currency
All amounts are in Canadian dollars.
Total disclosed transactions include every transaction with a disclosed amount in the period: venture rounds, grants, private placements, public-market financings (including debt and secondary offerings) and the disclosed price of acquisitions. Pending acquisitions are counted at their announced base price.
Amounts in other currencies are converted using the Bank of Canada’s annual average exchange rate for the year of the transaction. Because no full-year average is available for 2026, transactions this year use the average from Jan. 2 to Oct. 16: US$1 = $1.3872, €1 = $1.6076, £1 = $1.8638 and A$1 = $0.9758.
For the provincial comparison, funding totals for companies outside Alberta are exported from Dealroom in U.S. dollars and converted at the 2026 rate above. Alberta’s total comes directly from the Start Alberta export in Canadian dollars.
Venture rounds include Angel, Seed, Early VC, lettered series (Series A, B and so on), Late VC, Growth Equity VC and Private Placement VC.
Early-stage rounds are Seed and Early VC rounds, counted whether or not the amount was disclosed. Early VC is Dealroom’s label for an early venture round where the series isn’t specified.
Bootstrapped companies are those with no recorded outside investment tracked in Dealroom.
Segmentation and taxonomy
The taxonomy groups core Life Sciences companies by sub-industry and then by segment, using Dealroom tags and technologies. A company can sit in more than one segment. The technology-enabled branch is a tag-based view across both sub-industries and also uses the AI and machine learning technology fields.
|
Branch |
Segment |
Dealroom tags and technologies used |
|---|---|---|
|
Biotechnology |
Oncology |
oncology |
|
Biotechnology |
Genomics and precision medicine |
dna, rna, genetics and genomics, genome engineering, precision medicine, proteomics, gene therapy, mrna medicines |
|
Biotechnology |
Diagnostics and testing |
medical testing, testing, health diagnostics |
|
Pharmaceuticals |
Drug development and delivery |
drug development, drug delivery systems, vaccines |
|
Pharmaceuticals |
Natural health products |
dietary supplements, health supplements, cannabis, psychedelic drugs, nutrition |
|
Technology-enabled |
AI and data-driven R&D |
artificial intelligence, machine learning, big data, data analytics, ai drug discovery, techbio |
|
Technology-enabled |
Tech for biotech and pharma |
tech for biotech and pharm |
Data cleaning and limitations
Duplicate round rows are removed so each round counts once. Figures reflect what companies disclose, so totals are lower bounds.
About Start Alberta
Initiated by Alberta Enterprise Corporation (AEC), A100 and the Venture Capital Association of Alberta (VCAA) and in collaboration with a wide group of community partners, Start Alberta provides real-time data for founders, investors, corporates and government stakeholders, cataloguing the collective regional tech ecosystem.
Operated by the A100 since 2021, Start Alberta is the most comprehensive database on startups and funding in the province, providing insights on the health of the regional innovation economy while showcasing the Alberta startup ecosystem to the world.
|
|
|
|
|---|
Built with Shorthand